Human Herpesvirus 8

• HHV-8 is a gammaherpesvirus linked to specific cancers, especially in those with weakened immune systems.
• It is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman disease.
• Transmission primarily occurs through saliva, sexual contact, and organ transplantation.
• Prevention focuses on safe sexual practices, screening for organ donors, and managing immunosuppression.
• Early diagnosis and management are vital for mitigating the severe health consequences associated with HHV-8 infection.

What is Human Herpesvirus 8 (HHV-8)?

Human Herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), is a DNA virus belonging to the gammaherpesvirus subfamily. It is recognized as the etiological agent for several lymphoproliferative disorders and malignancies. Unlike many other herpesviruses that cause common infections, HHV-8 is primarily associated with specific cancers, particularly in individuals with compromised immune systems, such as those with HIV/AIDS or organ transplant recipients. The virus establishes a latent infection in host cells, meaning it can persist in the body for life, reactivating under certain conditions to cause disease. Understanding what is human herpesvirus 8 involves recognizing its unique ability to manipulate host cell pathways, contributing to cellular proliferation and evasion of immune surveillance. This complex interplay between the virus and the host immune system determines the progression from asymptomatic infection to overt disease.

HHV-8 Associated Diseases and Manifestations

Human Herpesvirus 8 associated diseases primarily include three distinct conditions: Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). Kaposi’s sarcoma is the most common HHV-8-associated malignancy, characterized by the growth of abnormal blood vessels that form lesions on the skin, mucous membranes, lymph nodes, and internal organs. The human herpesvirus 8 symptoms and causes for these conditions are directly linked to the viral infection. For instance, in KS, the virus infects endothelial cells, leading to their uncontrolled proliferation and the formation of characteristic purple or brown lesions. PEL involves the proliferation of B-lymphocytes infected with HHV-8, typically in body cavities. MCD, when associated with HHV-8, often presents with systemic inflammatory symptoms due to excessive cytokine production.

• Kaposi’s Sarcoma (KS): A vascular tumor that can affect the skin, mouth, lymph nodes, and internal organs. It is particularly prevalent in individuals with HIV/AIDS, where it is often aggressive and can lead to significant morbidity.
• Primary Effusion Lymphoma (PEL): A rare and aggressive form of non-Hodgkin lymphoma that typically presents as malignant effusions in body cavities (pleural, peritoneal, pericardial) without a solid tumor mass. It is almost exclusively found in immunocompromised individuals.
• Multicentric Castleman Disease (MCD): A rare lymphoproliferative disorder characterized by enlarged lymph nodes in multiple regions of the body, fever, night sweats, and weight loss. HHV-8 is implicated in a significant proportion of MCD cases, especially in HIV-positive individuals, where it drives the overproduction of inflammatory cytokines.

These diseases underscore the oncogenic potential of HHV-8, making it a significant public health concern, especially in regions with high rates of HIV infection. Early recognition of these manifestations is crucial for timely intervention and improved patient outcomes.

HHV-8 Transmission and Prevention

HHV-8 transmission and prevention strategies are critical for controlling the spread of this oncogenic virus. The primary routes of transmission vary by geographic region and population group but generally include close contact. The virus is commonly transmitted through saliva, particularly via deep kissing or sharing saliva-contaminated items. Sexual contact is another significant mode of transmission, especially among men who have sex with men (MSM), where the virus can be found in genital secretions. Additionally, HHV-8 can be transmitted through organ transplantation from an infected donor to a recipient, and vertically from mother to child, though this is less common and often depends on the mother’s viral load.

Prevention efforts focus on reducing exposure to the virus. For sexually active individuals, practicing safe sex, including consistent condom use, can help reduce the risk of transmission. Screening of organ donors for HHV-8 infection is crucial to prevent transmission to immunocompromised recipients, as post-transplant HHV-8 infection can lead to severe disease. For individuals living with HIV, effective antiretroviral therapy (ART) can significantly reduce the risk of developing HHV-8-associated diseases by improving immune function and reducing viral replication. Public health awareness campaigns about the modes of transmission can also play a role in limiting its spread. According to the Centers for Disease Control and Prevention (CDC), the prevalence of HHV-8 varies globally, with higher rates observed in sub-Saharan Africa and the Mediterranean basin compared to North America and Northern Europe, reflecting differences in transmission patterns and risk factors.